Inhibitors of platelet aggregation
US5747496A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Oct 31, 1996 |
| Grant date | May 5, 1998 |
| Priority date | — |
| Expiry date | Oct 31, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of the formula (I) ##STR1## wherein B is O or CH.sub.2 ; PA1 X is selected from NR.sup.1 R.sup.2, SR.sup.1, and C.sub.1 -C.sub.7 alkyl; PA1 Y is selected SR.sup.1, NR.sup.1 R.sup.2, and C.sub.1 -C.sub.7 alkyl; PA1 R.sup.1 and R.sup.2 is each and independently selected from H, or C.sub.1 -C.sub.7 alkyl optionally substituted upon or within the alkyl chain by one or more of O, S, N or halogen; PA1 R.sup.3 and R.sup.4 are both H, or R.sup.3 and R.sup.4 together form a bond; PA1 A is COOH, C(O)NH(CH.sub.2).sub.p COOH, C(O)N(CH.sub.2).sub.q COOH!.sub.2, C(O)NHCH(COOH)(CH.sub.2).sub.r COOH, or 5-tetrazolyl, wherein p, q and r is each and independently 1, 2 or 3; as well as pharmaceutically acceptable salts and prodrugs thereof, pharmaceutical compositions comprising the novel compounds and use of the compounds in therapy. Also within the scope of the invention are novel intermediates to the novel compounds. The novel compounds are in particular useful in the prevention of platelet aggregation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.